Akcea Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-207-0202
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$64.87 million
Profitability
Miscellaneous
Employees248
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable
Akcea Therapeutics (NASDAQ:AKCA) Frequently Asked Questions
What is Akcea Therapeutics' stock symbol?
Akcea Therapeutics trades on the NASDAQ under the ticker symbol "AKCA."
How were Akcea Therapeutics' earnings last quarter?
Akcea Therapeutics Inc (NASDAQ:AKCA) released its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.38) by $0.02. The company earned $26.62 million during the quarter, compared to analysts' expectations of $25.78 million. Akcea Therapeutics had a negative net margin of 65.62% and a negative return on equity of 43.87%. The company's revenue for the quarter was up 45.3% compared to the same quarter last year. During the same period last year, the business earned ($0.85) earnings per share. View Akcea Therapeutics' Earnings History.
When is Akcea Therapeutics' next earnings date?
What price target have analysts set for AKCA?
4 Wall Street analysts have issued 12 month price targets for Akcea Therapeutics' shares. Their forecasts range from $31.00 to $45.00. On average, they expect Akcea Therapeutics' share price to reach $39.6667 in the next twelve months. This suggests a possible upside of 86.4% from the stock's current price. View Analyst Price Targets for Akcea Therapeutics.
What is the consensus analysts' recommendation for Akcea Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akcea Therapeutics in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akcea Therapeutics.
Has Akcea Therapeutics been receiving favorable news coverage?
Press coverage about AKCA stock has been trending negative this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Akcea Therapeutics earned a news impact score of -2.3 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Akcea Therapeutics.
Who are some of Akcea Therapeutics' key competitors?
Some companies that are related to Akcea Therapeutics include Jazz Pharmaceuticals (JAZZ), Bausch Health Companies (BHC), Teva Pharmaceutical Industries (TEVA), Beigene (BGNE), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), Horizon Therapeutics (HZNP), Ascendis Pharma A/S (ASND), GW Pharmaceuticals PLC- (GWPH), ACADIA Pharmaceuticals (ACAD), Blueprint Medicines (BPMC), FibroGen (FGEN), Allakos (ALLK) and Mirati Therapeutics (MRTX).
What other stocks do shareholders of Akcea Therapeutics own?
Who are Akcea Therapeutics' key executives?
Akcea Therapeutics' management team includes the folowing people:
- Ms. Paula Soteropoulos, CEO & Director (Age 51)
- Mr. Michael F. MacLean, Chief Financial Officer (Age 53)
- Dr. Louis St. Laurence O'Dea FRCPC, MB, BCh, BAO, FRCP(C), Chief Medical Officer (Age 68)
- Ms. Sarah Boyce, Pres & Director (Age 47)
- Mr. Jeffrey M. Goldberg, Chief Operating Officer (Age 46)
When did Akcea Therapeutics IPO?
(AKCA) raised $125 million in an initial public offering (IPO) on Friday, July 14th 2017. The company issued 9,600,000 shares at $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities served as the underwriters for the IPO and BMO Capital Markets was co-manager.
Who are Akcea Therapeutics' major shareholders?
Akcea Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.05%), Vanguard Group Inc. (1.72%), Morgan Stanley (0.24%), Northern Trust Corp (0.21%), Alps Advisors Inc. (0.21%) and Charles Schwab Investment Management Inc. (0.10%). Company insiders that own Akcea Therapeutics stock include Ionis Pharmaceuticals Inc, Jeff Marc Goldberg, Paula Soteropoulos and Sarah Boyce. View Institutional Ownership Trends for Akcea Therapeutics.
Which major investors are selling Akcea Therapeutics stock?
AKCA stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, AQR Capital Management LLC, Zurcher Kantonalbank Zurich Cantonalbank and BNP Paribas Arbitrage SA. Company insiders that have sold Akcea Therapeutics company stock in the last year include Jeff Marc Goldberg, Paula Soteropoulos and Sarah Boyce. View Insider Buying and Selling for Akcea Therapeutics.
Which major investors are buying Akcea Therapeutics stock?
AKCA stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Alps Advisors Inc., Morgan Stanley, Bank of America Corp DE, BlackRock Inc., Renaissance Technologies LLC, GSA Capital Partners LLP and Jefferies Group LLC. View Insider Buying and Selling for Akcea Therapeutics.
How do I buy shares of Akcea Therapeutics?
Shares of AKCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Akcea Therapeutics' stock price today?
One share of AKCA stock can currently be purchased for approximately $21.28.
How big of a company is Akcea Therapeutics?
Akcea Therapeutics has a market capitalization of $1.98 billion and generates $64.87 million in revenue each year. The company earns $-225,820,000.00 in net income (profit) each year or ($2.74) on an earnings per share basis. Akcea Therapeutics employs 248 workers across the globe.View Additional Information About Akcea Therapeutics.
What is Akcea Therapeutics' official website?
How can I contact Akcea Therapeutics?
Akcea Therapeutics' mailing address is 22 BOSTON WHARF RD 9TH FLOOR, BOSTON MA, 02210. The company can be reached via phone at 617-207-0202 or via email at [email protected]
MarketBeat Community Rating for Akcea Therapeutics (NASDAQ AKCA)
MarketBeat's community ratings are surveys of what our community members think about Akcea Therapeutics and other stocks. Vote "Outperform" if you believe AKCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
